A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

NCT05918133 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

TNBC

Interventions

DRUG: PM8002
DRUG: nab-paclitaxel

Sponsor

Biotheus Inc.